Skip to Content

Generic Velphoro Availability

Last updated on July 7, 2021.

Velphoro is a brand name of sucroferric oxyhydroxide, approved by the FDA in the following formulation(s):

VELPHORO (ferric oxyhydroxide - tablet, chewable;oral)

  • Manufacturer: VIFOR FRESENIUS
    Approval date: November 27, 2013
    Strength(s): EQ 500MG IRON [RLD]

Has a generic version of Velphoro been approved?

No. There is currently no therapeutically equivalent version of Velphoro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Velphoro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,624,855

    Patent expiration dates:

    • November 26, 2034
      ✓ 
      Drug product
  • Patent 10624855*

    Patent expiration dates:

    • May 26, 2035
  • Patent 10,682,376

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 10682376*

    Patent expiration dates:

    • May 13, 2029
  • Patent 10,695,367

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 10695367*

    Patent expiration dates:

    • May 13, 2029
  • Patent 10,925,896

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 10925896*

    Patent expiration dates:

    • May 13, 2029
  • Patent 10,925,897

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 10925897*

    Patent expiration dates:

    • May 13, 2029
  • Patent 10,933,090

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 10933090*

    Patent expiration dates:

    • May 13, 2029
  • Patent 11,013,761

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 11013761*

    Patent expiration dates:

    • May 13, 2029
  • Patent 11,013,762

    Patent expiration dates:

    • November 13, 2028
      ✓ 
      Drug product
  • Patent 11013762*

    Patent expiration dates:

    • May 13, 2029
  • Pharmaceutical compositions
    Patent 9,561,251
    Issued: February 7, 2017
    Assignee(s): Vifor Fresenius Medical Care Renal Pharma Ltd.

    Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

    Patent expiration dates:

    • January 23, 2030
      ✓ 
      Patent use: CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
      ✓ 
      Drug product
    • July 23, 2030
      ✓ 
      Pediatric exclusivity

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.